Influence of Oxytocin Usage and Dose Difference During Delivery on Pregnancy Outcome of VBAC Pregnant Women.

In order to explore the influence of oxytocin usage and dose difference during delivery on the pregnancy outcome of VBAC pregnant women, the clinical data of 166 VBAC pregnant women from January 2017 to March 2020 are retrospectively analyzed. All women are divided into different groups according to the usage of oxytocin during delivery and the oxytocin dose difference. Binary logistic regression is used to analyze the factors affecting the pregnancy outcome of pregnant women with VBAC. The gestational weeks and the thickness of the lower uterine segment in the oxytocin group are significantly more than those in the nonoxytocin group ( < 0.05). The time of the first stage of labor, second stage of labor, and total stage of labor in the oxytocin group are significantly longer than the nonoxytocin group ( < 0.05). The proportion of entering NICU in the oxytocin group is significantly lower than the nonoxytocin group ( < 0.05). There is no significant difference in labor duration and pregnancy outcome between low-dose and medium-dose oxytocin groups. Binary logistic regression analysis shows that prenatal BMI <30 kg/cm, gestational age ≤40 weeks, history of vaginal delivery, uterine expansion, and admission to hospital are the influencing factors for pregnancy success of pregnant women with VBAC. The usage of oxytocin in VBAC pregnant women during delivery may increase the duration of labor. For those with poor uterine contraction, oxytocin can be increased to 4∼18 mU/min to speed up the labor process, without increasing the risk of adverse pregnancy outcomes.